Literature DB >> 3205675

Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation.

T B Vree1, W J Wijnands, A M Baars, Y A Hekster.   

Abstract

Nalidixic acid is metabolized by hydroxylation to 7-hydroxymethylnalidixic acid[[ and then by oxidation to 7-carboxynalidixic acid.[[ The half-lives of the two elimination phases of nalidixic acid are 0.75 and 2.5 h. The apparent half-lives of the metabolite 7-hydroxymethylnalidixic acid are 2.5 and 5.5 h. Plasma protein binding of nalidixic acid is 95% and that of 7-hydroxymethylnalidixic acid 65%. The renal clearance of nalidixic acid varies between 2 and 25 ml/min and that of 7-hydroxymethylnalidixic acid between 37 and 162 ml/min. Of nalidixic acid 42% is glucuronidated and 40% hydroxylated. Of the hydroxy metabolite 57% is glucuronidated and 32% excreted unchanged. 7-Carboxynalidixic acid is excreted in the urine and is not glucuronidated. The variations in the glucuronidation/hydroxylation ratio of nalidixic acid and the glucuronidation/renal excretion ratio of the 7-hydroxymethyl metabolite belong to a normal distribution.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3205675     DOI: 10.1007/bf01956870

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  20 in total

1.  The effect of the 4-quinolone enoxacin on plasma theophylline concentrations.

Authors:  W J Wijnands; T B Vree; C L Van Herwaarden
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

2.  [New investigation of the pharmacokinetics of nalidixic acid. I. Serum and urinary levels with normal renal function].

Authors:  P Brühl; G Gundlach; K Wintjes; W Eichner; H P Bastian
Journal:  Arzneimittelforschung       Date:  1973-09

Review 3.  Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs.

Authors:  E M Faed
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

4.  High-performance liquid chromatographic analysis of nalidixic acid and hydroxynalidixic acid in plasma with a dynamic anion-exchange system.

Authors:  R H Sorel; A Hulshoff; C Snelleman
Journal:  J Chromatogr       Date:  1980-11-14

5.  [Effect of probenecid on the pharmacokinetics of nalidixic acid].

Authors:  N Ferry; G Cuisinaud; N Pozet; P Y Zech; J Sassard
Journal:  Therapie       Date:  1982 Nov-Dec       Impact factor: 2.070

6.  Pharmacokinetic model for nalidixic acid in man. II. Parameters for absorption, metabolism, and elimination.

Authors:  G A Portmann; E W McChesney; H Stander; W E Moore
Journal:  J Pharm Sci       Date:  1966-01       Impact factor: 3.534

7.  pH-dependent rearrangement of the biosynthetic ester glucuronide of valproic acid to beta-glucuronidase-resistant forms.

Authors:  R G Dickinson; W D Hooper; M J Eadie
Journal:  Drug Metab Dispos       Date:  1984 Mar-Apr       Impact factor: 3.922

8.  Pharmacokinetics of nalidixic acid associated with sodium citrate.

Authors:  N Ferry; G Cuisinaud; J Sassard; N Pozet; P Y Zech
Journal:  Biopharm Drug Dispos       Date:  1984 Jul-Sep       Impact factor: 1.627

9.  Nalidixic acid kinetics after single and repeated oral doses.

Authors:  N Ferry; G Cuisinaud; N Pozet; P Y Zech; J Sassard
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

10.  Determination of nalidixic acid and its two major metabolites in human plasma and urine by reversed-phase high-performance liquid chromatography.

Authors:  G Cuisinaud; N Ferry; M Seccia; N Bernard; J Sassard
Journal:  J Chromatogr       Date:  1980-03-14
View more
  3 in total

1.  The effect of infinitesimal drug dilutions on the pharmacokinetics of nalidixic acid and atenolol.

Authors:  N Ferry; N Bernard; N Pozet; E Gardes; M Bruguier; G Cuisinaud; J Sassard
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

2.  Direct gradient reversed-phase HPLC analysis and preliminary pharmacokinetics of nalidixic acid, 7-hydroxymethylnalidixic acid, 7-carboxynalidixic acid, and their corresponding glucuronide conjugates in humans.

Authors:  T B Vree; M van den Biggelaar-Martea; E W van Ewijk-Beneken Kolmer; Y A Hekster
Journal:  Pharm World Sci       Date:  1993-06-18

3.  Mechanistic insights into synergy between nalidixic acid and tetracycline against clinical isolates of Acinetobacter baumannii and Escherichia coli.

Authors:  Amit Gaurav; Varsha Gupta; Sandeep K Shrivastava; Ranjana Pathania
Journal:  Commun Biol       Date:  2021-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.